anti-PD1/masked IL-2 therapeutic
/ OSE Immunotherapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 17, 2024
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
(OSE Immunotherapeutics Press Release)
- "OSE Immunotherapeutics SA...announced it will be presenting its novel OSECYTOMASK Cis-Demasking cytokine technology in oral presentations selected for international conferences....The presentations highlight the rational design of the technology through two first preclinical programs based on anti-PD1 masked cytokine (IL-2, IL-15) in oncology with conditional CisDemasking and Cis-Potentiation of tumor-specific T cells expressing PD1 or other immune targets."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1